Compare PRG & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | CGEM |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2020 | 2020 |
| Metric | PRG | CGEM |
|---|---|---|
| Price | $39.49 | $22.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $50.00 | $30.13 |
| AVG Volume (30 Days) | 431.0K | ★ 669.9K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $2,409,223,000.00 | N/A |
| Revenue This Year | $23.77 | N/A |
| Revenue Next Year | $7.91 | $5.20 |
| P/E Ratio | $21.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.80 | $5.68 |
| 52 Week High | $47.73 | $23.19 |
| Indicator | PRG | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 58.77 |
| Support Level | $38.13 | $11.87 |
| Resistance Level | $41.14 | $23.19 |
| Average True Range (ATR) | 1.15 | 1.01 |
| MACD | -0.15 | -0.08 |
| Stochastic Oscillator | 26.57 | 55.78 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.